Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41140 | 0.94 | ALDH1A1 (0.42) | ALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL38202 | 0.94 | ALDH1A1 (0.42) | ALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL28544762 | 0.92 | ALDH1A1 (0.40) | ALDH1A1RAB9AKMT2A | |
| SCHEMBL769959 | 0.90 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL25097 | 0.90 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL769634 | 0.90 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL1615164 | 0.84 | — | — | |
| SCHEMBL589437 | 0.84 | MAOA (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL7951300 | 0.84 | ALDH1A1 (0.33) | ALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL26567 | 0.84 | MAOA (0.41) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294246-B2 | Substituted boronic acids and boronate esters as immunoproteasome inhibitors | MERCK PATENT GMBH (DE) | 2019-05-21 | — | — | US | claimed |
| CN-103052642-A | Crystal of tricyclic pyrazolopyrimidine derivative | DAIICHI SANKYO CO LTD | 2013-04-17 | — | — | CN | claimed |
| CN-102333781-A | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO CO LTD | 2012-01-25 | — | — | CN | claimed |
| WO-2009003952-A2 | COLUMN AND METHOD FOR PREPARING A BIOLOGICAL SAMPLE FOR PROTEIN PROFILING | PRONOTA N.V. (BE) | 2009-01-08 | — | — | WO | claimed |
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | TELIX PHARMACEUTICALS INNOVATIONS PTY LTD (AU) | 2024-07-18 | — | — | US | disclosed |
| EP-4399178-A1 | PROCESS FOR THE PRODUCTION OF HYDROGEN THROUGH ELECTRIFICATION OF WATER GAS SHIFT REACTION | TotalEnergies OneTech (FR) | 2024-07-17 | — | — | EP | disclosed |
| EP-4399236-A1 | DEGRADABLE CURING AGENTS, COMPOSITIONS AND CURABLE COMPOSITIONS THEREOF | Vito NV (BE) | 2024-07-17 | — | — | EP | disclosed |
| CN-118355022-A | Nucleoside analogues for the treatment of parasitic infections | 安特卫普大学 | 2024-07-16 | — | — | CN | disclosed |
| CN-118339204-A | Dual catalyst composition | 道达尔能源一技术比利时公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118339205-A | Polymerization process using dual catalyst composition | 道达尔能源一技术比利时公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240216291-A1 | Nucleic Acid Containing Nanoparticles | BIO TRIP B V (NL) | 2024-07-04 | — | — | US | disclosed |
| US-20240209127-A1 | NEW METALLOCENE CATALYST AND USE THEREOF | TOTALENERGIES ONETECH BELGIUM (BE) | 2024-06-27 | — | — | US | disclosed |
| US-6297008-B1 | SIMPLE, SENSITIVE AND ACCURATE PROCESS BY HYBRIDIZING PROBE TO TARGET NUCLEIC ACID, ASSOCIATING CHEMILUMINESCENT COMPOUND OF DEFINED STRUCTURE WITH FORMED DOUBLE-STRAND, EXPOSING COMPOUND TO ACTIVATING COMPOUNDS, THEN DETECTING LUMINESCENCE | CANON KABUSHIKI KAISHA (JP) | 2001-10-02 | — | — | US | disclosed |
| CN-1219165-A | Tricyclic compounds having activity specific for integrins, in particular alpha v beta 3 integrins, process and intermediates for their preparation, their use as medicaments and pharmaceutical compositions containing them | HOECHST MARION ROUSSEL CO (FR) | 1999-06-09 | — | — | CN | disclosed |
| US-5846991-A | Pyrazole derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-08 | — | — | US | disclosed |
| US-5840909-A | Pyrazole derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| US-5817828-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS; VISION DEFECTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0837141-A2 | Process for detecting target nucleic acid, process for quantifying the same, and pyrylium compound for chemiluminescence analysis | CANON KABUSHIKI KAISHA (JP) | 1998-04-22 | — | — | EP | disclosed |
| US-5721264-A | EXHIBIT ANTAGONISTIC EFFECT AGAINST ANGIOTENSIN II; USEFUL FOR PREVENTION AND REMEDY OF HYPERTENSION, CONGESTIVE HEARTFAILURE, CHRONIC RENAL INSUFFICIENCY, ALDOSTERONISM | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-24 | — | — | US | disclosed |
| EP-0693480-A1 | PYRAZOLE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1996-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | KLK3, FOLH1, CA14 | ALDH1A1 3095/4885MEN1 81/4885RAB9A 292/4885 |
| US-20240216291-A1 | Nucleic Acid Containing Nanoparticles | APOB, APOL1, TLR3 | ALDH1A1 4030/4885MEN1 3590/4885RAB9A 2996/4885 |
| US-10294246-B2 | Substituted boronic acids and boronate esters as immunoproteasome inhibitors | PSMB7, PSMA7, PSMB11 | ALDH1A1 2896/4885MEN1 785/4885RAB9A 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.